| Up
2005D-0106:
Guidance for Industry on Systemic Lupus Erythematosus Developing
Drugs for Treatment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| GDL1
|
| 03/28/2005
|
| 03/28/2005
|
| Federal
Government
|
| Guidance
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
| Signature:
|
| Guidance
|
|
|
|
|
|
|
|
| NAD1
|
|
|
| 03/28/2005
|
| FDA
|
| FDA
|
| 03/29/2005
|
| 15868-15868
|
| 06/27/2005
|
| pdf
|
|
|
|
|
| Signature:
|
| Jeffrey Shuren
|
|
|
|
|
| EMC1
|
| 06/21/2005
|
| 06/21/2005
|
| Drug Industry
|
| Abbott Laboratories
(Abbott)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Douglas L. Sporn
|
|
|
|
|
| C1
|
| 06/27/2005
|
| 06/24/2005
|
| Drug Industry
|
| Genentech, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Robert L. Garnick, PhD
|
|
Top | Up
Page last updated
July 14, 2005
kk
Dockets Home Page | Dockets
Contacts and Location | Operating
Status | Item
Code Definitions | Federal
Register
FDA Home Page | Search
FDA Site | FDA A-Z Index
| Contact FDA
FDA/Dockets Management |
